A Dark Vector Cognition product

Stryker 10-Q 2026-09-30

SYK · CIK 310764 · Form 10-Q · Period ended September 30, 2026 · Filed October 30, 2026

Revenue rose 7.6% to $6.52 billion. Operating margin was 15.9%, against 18.7% a year earlier. Net income was $753 million.

9 sections, 119K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$6.52B$6.06B+7.6%
Operating income$1.03B$1.14B-8.9%
Net income$753M$859M-12.3%
Diluted EPS$1.96$2.22-11.7%
Cash and equivalents$3.27Bn/an/a
Operating margin*15.9%18.7%-2.9 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 95 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-13149

strykerlogoa74.jpg

STRYKER CORP****ORATION

(Exact name of registrant as specified in its charter)

Michigan38-1239739
(State of incorporation)(I.R.S. Employer Identification No.)
1941 Stryker WayPortage,Michigan49002
(Address of principal executive offices)(Zip Code)
(269)385-2600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.10 Par ValueSYKNew York Stock Exchange
2.125% Notes due 2027SYK27New York Stock Exchange
3.375% Notes due 2028SYK28New York Stock Exchange
0.750% Notes due 2029SYK29New York Stock Exchange
2.625% Notes due 2030SYK30New York Stock Exchange
1.000% Notes due 2031SYK31New York Stock Exchange
3.375% Notes due 2032SYK32New York Stock Exchange
3.625% Notes due 2036SYK36New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days.Yes ☒No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant

to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant

was required to submit such files).Yes ☒No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting

company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting

company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐Emerging growth company☐
Non-accelerated filer☐Smaller reporting company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ☐No ☒

There were 380,691,004 shares of Common Stock, $0.10 par value, on September 30, 2026.

Dollar amounts are in millions except per share amounts or as otherwise specified.1
STRYKER CORPORATION2026 Third Quarter Form 10-Q

PART I – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

Stryker Corporation and Subsidiaries

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)

Three MonthsNine Months
2026202520262025
Net sales$6,520$6,057$19,129$17,945
Cost of sales2,2722,2056,5736,508
Gross profit$4,248$3,852$12,556$11,437
Research, development and engineering expenses4334101,2801,222
Selling, general and administrative expenses2,3132,0456,8236,424
Amortization of intangible assets175189530543
Goodwill and other impairments29373294163
Total operating expenses$3,214$2,717$8,927$8,352
Operating income$1,034$1,135$3,629$3,085
Interest expense(143)(157)(432)(453)
Other income10651214177
Earnings before income taxes$997$1,029$3,411$2,809
Income taxes244170637412
Net earnings$753$859$2,774$2,397
Net earnings per share of common stock:
Basic$1.97$2.25$7.24$6.27
Diluted$1.96$2.22$7.19$6.20
Weighted-average shares outstanding (in millions):
Basic382.2382.4382.9382.1
Effect of dilutive employee stock compensation2.54.32.94.4
Diluted384.7386.7385.8386.5
Cash dividends declared per share of common stock$0.88$0.84$2.64$2.52

Anti-dilutive shares excluded from the calculation of dilutive employee stock options were de minimis in all periods.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)

Three MonthsNine Months
2026202520262025
Net earnings$753$859$2,774$2,397
Other comprehensive income (loss), net of tax:
Marketable securities————
Pension plans———2
Unrealized gains (losses) on designated hedges(28)8(59)11
Financial statement translation11(12)153(486)
Total other comprehensive income (loss), net of tax$(17)$(4)$94$(473)
Comprehensive income$736$855$2,868$1,924

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.2
STRYKER CORPORATION2026 Third Quarter Form 10-Q

CONSOLIDATED BALANCE SHEETS

September 30December 31
20262025
(Unaudited)
Assets
Current assets
Cash and cash equivalents$3,271$4,011
Marketable securities—89
Accounts receivable, less allowance of $226 ($216 in 2025)3,6934,039
Inventories:
Materials and supplies1,3771,349
Work in process484415
Finished goods3,8863,546
Total inventories$5,747$5,310
Prepaid expenses and other current assets1,4721,306
Total current assets$14,183$14,755
Property, plant and equipment:
Land, buildings and improvements1,8221,793
Machinery and equipment6,1765,744
Total property, plant and equipment$7,998$7,537
Less allowance for depreciation3,9443,661
Property, plant and equipment, net$4,054$3,876
Goodwill19,32619,291
Other intangibles, net5,5425,681
Noncurrent deferred income tax assets9011,098
Other noncurrent assets3,2413,143
Total assets$47,247$47,844
Liabilities and shareholders' equity
Current liabilities
Accounts payable$1,634$1,799
Accrued compensation1,3631,595
Income taxes65418
Dividends payable335337
Accrued expenses and other liabilities2,3492,645
Current maturities of debt7541,000
Total current liabilities$6,500$7,794
Long-term debt, excluding current maturities14,17614,859
Income taxes413402
Other noncurrent liabilities2,7012,369
Total liabilities$23,790$25,424
Shareholders' equity
Common stock, $0.10 par value3838
Additional paid-in capital2,7642,597
Retained earnings21,24820,472
Accumulated other comprehensive loss(593)(687)
Total shareholders' equity$23,457$22,420
Total liabilities and shareholders' equity$47,247$47,844

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.3
STRYKER CORPORATION2026 Third Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)

Three MonthsNine Months
2026202520262025
Common stock shares outstanding (in millions)
Beginning383.5382.3382.5381.4
Issuance of common stock under stock compensation and benefit plans0.20.11.21.0
Repurchase of common stock(3.0)—(3.0)—
Ending380.7382.4380.7382.4
Common stock
Beginning$38$38$38$38
Issuance of common stock under stock compensation and benefit plans————
Repurchase of common stock————
Ending$38$38$38$38
Additional paid-in capital
Beginning$2,711$2,492$2,597$2,361
Issuance of common stock under stock compensation and benefit plans7(1)(20)(3)
Repurchase of common stock(21)—(21)—
Share-based compensation6762208195
Ending$2,764$2,553$2,764$2,553
Retained earnings
Beginning$21,815$19,423$20,472$18,528
Net earnings7538592,7742,397
Repurchase of common stock(987)—(987)—
Cash dividends declared(333)(322)(1,011)(965)
Ending$21,248$19,960$21,248$19,960
Accumulated other comprehensive income (loss)
Beginning$(576)$(762)$(687)$(293)
Other comprehensive income (loss)(17)(4)94(473)
Ending$(593)$(766)$(593)$(766)
Total shareholders' equity$23,457$21,785$23,457$21,785

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.4
STRYKER CORPORATION2026 Third Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Nine Months
20262025
Operating activities
Net earnings$2,774$2,397
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation361334
Amortization of intangible assets530543
Goodwill and other impairments294163
Share-based compensation208195
Sale of inventory stepped-up to fair value at acquisition—160
Deferred income tax (benefit) expense166191
Changes in operating assets and liabilities:
Accounts receivable320524
Inventories(468)(373)
Accounts payable(154)(205)
Accrued expenses and other liabilities(279)(78)
Income taxes(395)(577)
Other, net(54)(373)
Net cash provided by operating activities$3,303$2,901
Investing activities
Acquisitions, net of cash acquired(481)(4,950)
Purchases of marketable securities(23)(32)
Proceeds/(Purchases) of short-term investments—750
Proceeds from sales of marketable securities11240
Purchases of property, plant and equipment(605)(493)
Proceeds from the sale of the Spinal Implants business—165
Other investing, net(14)(41)
Net cash used in investing activities$(1,011)$(4,561)
Financing activities
Proceeds (payments) on short-term borrowings, net2471
Proceeds from issuance of long-term debt—2,979
Payments on long-term debt(1,000)(650)
Payments of dividends(1,012)(963)
Repurchases of common stock(1,000)—
Cash paid for taxes from withheld shares(156)(132)
Other financing, net(77)(29)
Net cash provided by (used in) financing activities$(2,998)$1,206
Effect of exchange rate changes on cash and cash equivalents(34)58
Change in cash and cash equivalents$(740)$(396)
Cash and cash equivalents at beginning of period4,0113,652
Cash and cash equivalents at end of period$3,271$3,256

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.5
STRYKER CORPORATION2026 Third Quarter Form 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated

Financial Statements contain all adjustments, including normal

recurring items, considered necessary to fairly present the

financial position of Stryker Corporation and its consolidated

subsidiaries ("Stryker," the "Company," "we," "us" or "our") on

September 30, 2026 and the results of operations for the three

and nine months 2026. The results of operations included in

these Consolidated Financial Statements may not necessarily be

indicative of our annual results. These statements should be read

in conjunction with our Annual Report on Form 10-K for 2025.

In the first quarter 2026 we announced a change in our

organizational structure. Our new Ortho Tech business combines

the orthopaedic instruments portfolio from our Instruments

business with the Mako and enabling technologies portfolio from

our Other Orthopaedics business. By bringing Mako, power tools,

cutting accessories, enabling technologies and the teams behind

these products together under one business, we are simplifying

the customer experience and striving to increase our speed to

market through focused innovation.

Following this reorganization we continue to have two business

segments, (i) MedSurg and Neurotechnology and (ii)

Orthopaedics, each of which comprise a reportable segment. All

historical segment financial information has been recast to

conform to this new reporting structure in our financial statements

and accompanying notes.

New Accounting Pronouncements Not Yet Adopted

In September 2025 the Financial Accounting Standards Board

(FASB) issued Accounting Standards Update (ASU) 2025-07

(Topics 815 and 606): Derivatives and Hedging: Derivatives

Scope Refinements and Revenue from Contracts with

Customers: Scope Clarification for Share-Based Noncash

Consideration from a Customer in a Revenue Contract. This

update expands the scope exception in Topic 815 to certain non-

exchange-traded contracts for which settlement is based on

operations or activities specific to one of the parties to the

contract. The update is effective for fiscal years beginning after

December 15, 2026 including interim periods within those fiscal

years. Early adoption is permitted. We are evaluating if the ASU

will have an impact on our Consolidated Financial Statements.

In September 2025 the FASB issued ASU 2025-06 (Subtopic

350-40): Intangibles - Goodwill and Other - Internal-Use

Software: Targeted Improvements to the Accounting for Internal-

Use Software. This update clarifies and modernizes the

accounting for costs related to internal-use software by removing

all references to project stages and clarifying that the probable-

to-complete threshold is not met if significant development

uncertainty exists. The update is effective for fiscal years

beginning after December 15, 2027 including interim periods

within those fiscal years. Early adoption is permitted. We are

evaluating if the ASU will have an impact on our Consolidated

Financial Statements.

In November 2024 the FASB issued ASU 2024-03 (Subtopic

220-40): Income Statement: Reporting Comprehensive Income -

Expense Disaggregation Disclosures which requires

disaggregation of certain expense captions into specified

categories in disclosures within the Notes to the Consolidated

Financial Statements. The new disclosure requirements are

effective for fiscal years beginning after December 15, 2026 and

interim periods within fiscal years beginning after December 15,

  1. Early adoption is permitted. We are evaluating these new

expanded disclosure requirements.

We evaluate all ASUs issued by the FASB for consideration of

their applicability. ASUs not included in our disclosures were

assessed and determined to be either not applicable or are not

expected to have a material impact on our Consolidated Financial

Statements.

Accounting Pronouncements Recently Adopted

On January 1, 2026 we adopted ASU 2025-05 (Topic 326):

Financial Instruments - Credit Losses: Measurement of Credit

Losses for Accounts Receivable and Contract Assets. This

update provides a practical expedient allowing entities to assume

that current conditions as of the balance sheet date will remain

unchanged for the remaining life of the asset when estimating

expected credit losses for current accounts receivable and

current contract assets arising from transactions accounted for

under Accounting Standards Codification 606, Revenue from

Contracts with Customers. The adoption of this update did not

have a material impact on our Consolidated Financial

Statements.

NOTE 2 - REVENUE RECOGNITION

Our policies for recognizing sales have not changed from those

described in our Annual Report on Form 10-K for 2025.

We disaggregate our net sales by business and geographic

location for each of our segments as we believe it best depicts

how the nature, amount, timing and certainty of our net sales and

cash flows are affected by economic factors.

In the first quarter 2026 we announced a change in our

organizational structure. Our new Ortho Tech business combines

the orthopaedic instruments portfolio (Orthopaedic Instruments)

from Instruments with Other Orthopaedics. In addition, Neuro

Cranial and the spine enabling technologies portfolio (Enabling

Technologies) from Other Orthopaedics were combined with the

remaining Instruments business to align with our internal

reporting structure. Ortho Tech includes sales related to

Orthopaedic Instruments of $535 and $492 and Other

Orthopaedics of $219 and $159 for the three months 2026 and

  1. For the nine months 2026 and 2025 Ortho Tech includes

sales related to Orthopaedic Instruments of $1,547 and $1,477

and Other Orthopaedics of $570 and $440. Instruments includes

sales related to Neuro Cranial of $670 and $637 and Enabling

Technologies of $28 and $45 for the three months 2026 and

  1. For the nine months 2026 and 2025 Instruments includes

sales related to Neuro Cranial of $1,957 and $1,816 and

Enabling Technologies of $82 and $108. We have reflected these

changes in all historical periods presented.

Dollar amounts are in millions except per share amounts or as otherwise specified.6
STRYKER CORPORATION2026 Third Quarter Form 10-Q
Net Sales by Business
Three MonthsNine Months
2026202520262025
MedSurg and Neurotechnology:
Instruments$996$949$2,919$2,705
Endoscopy1,0218962,8932,662
Medical1,0819853,1052,920
Vascular5665251,5791,429
$3,664$3,355$10,496$9,716
Orthopaedics:
Knees$635$628$1,998$1,907
Hips4534571,3921,366
Trauma and Extremities1,0109603,1172,862
Ortho Tech7546512,1171,917
Spinal Implants469$177
$2,856$2,702$8,633$8,229
Total$6,520$6,057$19,129$17,945
Net Sales by Geography
Three MonthsNine Months
2026202520262025
United States$4,950$4,571$14,385$13,565
International1,5701,4864,7444,380
Total$6,520$6,057$19,129$17,945

Costs to Obtain or Fulfill a Contract

We typically do not incur costs to fulfill a contract before a

product or service is provided to a customer due to the nature of

our products and services. Our costs to obtain contracts are

typically in the form of sales commissions paid to employees or

third-party agents. Certain sales commissions paid to employees

prior to recognition of sales are recorded as deferred contract

costs. We expense sales commissions associated with obtaining

a contract at the time of the sale or as incurred as the

amortization period is generally less than one year. These costs

have been presented within selling, general and administrative

expenses. On September 30, 2026 and December 31, 2025

deferred contracts costs recorded in our Consolidated Balance

Sheets were not significant.

Contract Assets and Liabilities

Our contract assets primarily relate to conditional rights to

consideration for work completed but not billed at the reporting

date. On September 30, 2026 and December 31, 2025 contract

assets recorded in our Consolidated Balance Sheets were not

significant.

Our contract liabilities arise as a result of consideration received

from customers at inception of contracts for certain businesses or

where the timing of billing for services precedes satisfaction of

our performance obligations. This occurs primarily when payment

is received upfront for certain multi-period extended service

contracts. Our contract liabilities of $960 and $1,024 on

September 30, 2026 and December 31, 2025 are classified within

accrued expenses and other liabilities and other noncurrent

liabilities in our Consolidated Balance Sheets based on the timing

of when we expect to complete our performance obligations.

Changes in contract liabilities during the nine months 2026 were

as follows:

September 30
2026
Beginning contract liabilities$1,024
Revenue recognized from beginning of year contract liabilities(615)
Net advance consideration received during the period551
Ending contract liabilities$960

Transfers and Servicing of Financial Assets

We sell certain customer lease agreements and the related

leased assets to third-party financial institutions to accelerate our

cash collection cycle. The lease receivables are sold without

recourse and are derecognized from our Consolidated Balance

Sheets at the time of sale. Under the terms of our arrangements,

we collect lease payments on behalf of the financial institutions

but maintain no other form of continuing involvement. Sales of

these lease agreements are classified as operating activities in

our Consolidated Statements of Cash Flows. Fees earned for our

servicing activities are immaterial. Revenue related to customer

lease agreements sold under these arrangements represented

less than 4% of our total revenue for the three and nine months

2026 and 2025.

NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS)

INCOME (AOCI)

Three Months 2026Pension PlansHedgesFinancial Statement TranslationTotal
Beginning$70$11$(657)$(576)
OCI1(31)30—
Income taxes—9(11)(2)
Reclassifications to:
Cost of sales—(5)—(5)
Interest expense—(2)—(2)
Other income(1)—(10)(11)
Income taxes—123
Net OCI$—$(28)$11$(17)
Ending$70$(17)$(646)$(593)
Three Months 2025Pension PlansHedgesFinancial Statement TranslationTotal
Beginning$6$34$(802)$(762)
OCI—19(4)15
Income taxes—(3)—(3)
Reclassifications to:
Cost of sales—(8)—(8)
Interest expense—(1)—(1)
Other income——(11)(11)
Income taxes—134
Net OCI$—$8$(12)$(4)
Ending$6$42$(814)$(766)
Nine Months 2026Pension PlansHedgesFinancial Statement TranslationTotal
Beginning$70$42$(799)$(687)
OCI2(41)186147
Income taxes110(10)1
Reclassifications to:
Cost of sales—(29)—(29)
Interest expense—(4)—(4)
Other income(4)—(30)(34)
Income taxes15713
Net OCI$—$(59)$153$94
Ending$70$(17)$(646)$(593)
Dollar amounts are in millions except per share amounts or as otherwise specified.7
STRYKER CORPORATION2026 Third Quarter Form 10-Q
Nine Months 2025Pension PlansHedgesFinancial Statement TranslationTotal
Beginning$4$31$(328)$(293)
OCI325(589)(561)
Income taxes(1)(2)128125
Reclassifications to:
Cost of sales—(13)—(13)
Interest expense—(2)—(2)
Other income——(33)(33)
Income taxes—3811
Net OCI$2$11$(486)$(473)
Ending$6$42$(814)$(766)

NOTE 4 - DERIVATIVE INSTRUMENTS

We use operational and economic hedges, foreign currency

exchange forward contracts, net investment hedges (both

derivative and non-derivative financial instruments) and interest

rate derivative instruments to manage the impact of currency

exchange and interest rate fluctuations on earnings, cash flow

and equity. We do not enter into derivative instruments for

speculative purposes. We are exposed to potential credit loss in

the event of nonperformance by counterparties on our

outstanding derivative instruments but do not anticipate

nonperformance by any of our counterparties. Should a

counterparty default, our maximum loss exposure is the asset

balance of the instrument. We have not changed our hedging

strategies, accounting practices or objectives from those

disclosed in our Annual Report on Form 10-K for 2025.

Foreign Currency Hedges
September 2026Cash FlowNet InvestmentNon- DesignatedTotal
Gross notional amount$1,967$2,552$3,256$7,775
Maximum term in years8.0
Fair value:
Other current assets$14$—$37$51
Other noncurrent assets214—16
Other current liabilities(36)(35)(11)(82)
Other noncurrent liabilities(3)(13)—(16)
Total fair value$(23)$(34)$26$(31)
December 2025Cash FlowNet InvestmentNon- DesignatedTotal
Gross notional amount$1,738$2,647$4,391$8,776
Maximum term in years8.7
Fair value:
Other current assets$33$—$11$44
Other noncurrent assets2——2
Other current liabilities(10)(71)(21)(102)
Other noncurrent liabilities(2)(66)—(68)
Total fair value$23$(137)$(10)$(124)

We had €2.3 billion at September 30, 2026 and December 31,

2025 in certain forward currency contracts designated as net

investment hedges, for which the maximum term is 8.0 years, to

hedge a portion of our investments in certain of our entities with

functional currencies denominated in Euros. In addition to these

derivative financial instruments designated as net investment

hedges, we had €5.0 billion at September 30, 2026 and

December 31, 2025 of senior unsecured notes designated as net

investment hedges to selectively hedge portions of our

investment in certain international subsidiaries. The currency

effects of our Euro-denominated senior unsecured notes are

reflected in AOCI within shareholders' equity where they offset

gains and losses recorded on our net investment in international

subsidiaries.

The total after-tax gain (loss) recognized in OCI related to

designated net investment hedges was $204 in the nine months

Currency Exchange Rate Gains (Losses) Recognized in Net

Earnings

Three MonthsNine Months
Derivative InstrumentRecognized in:2026202520262025
Cash FlowCost of sales$5$8$29$13
Net InvestmentOther income10113033
Non- DesignatedOther income(3)3(2)31
Total$12$22$57$77

Pretax gains (losses) on derivatives designated as cash flow

hedges of ($18) and net investment hedges of $28 recorded in

AOCI are expected to be reclassified to cost of sales and other

income in earnings within 12 months of September 30, 2026.

This cash flow hedge reclassification is primarily due to the sale

of inventory that includes previously hedged purchases. A

component of the AOCI amounts related to net investment

hedges is reclassified over the life of the hedge instruments as

we elected to exclude the initial value of the component related to

the spot-forward difference from the effectiveness assessment.

Interest Rate Hedges

Pretax gains of $6 recorded in AOCI related to interest rate

hedges closed in conjunction with debt issuances are expected to

be reclassified to interest expense in earnings within 12 months

of September 30, 2026. The cash flow effect of interest rate

hedges is recorded in cash flow from operations.

NOTE 5 - FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest

rates, credit and markets and our process for determining fair

value have not changed from those described in our Annual

Report on Form 10-K for 2025.

In the nine months 2026 we recorded $271 of contingent

consideration related to the acquisition of Amplitude Vascular

Systems, Inc. (AVS) described in Note 7.

In 2025 we assumed contingent consideration liabilities with a fair

value of $90 related to previous acquisitions made by Inari

Medical, Inc. (Inari). Refer to Note 7 for further information on the

acquisition of Inari.

There were no significant transfers into or out of any level of the

fair value hierarchy in 2026.

Assets Measured at Fair Value
September 30December 31
20262025
Cash and cash equivalents$3,271$4,011
Trading marketable securities339307
Level 1 - Assets$3,610$4,318
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$—$52
United States treasury debt securities—37
Total available-for-sale marketable securities$—$89
Foreign currency exchange forward contracts6746
Level 2 - Assets$67$135
Total assets measured at fair value$3,677$4,453
Dollar amounts are in millions except per share amounts or as otherwise specified.8
STRYKER CORPORATION2026 Third Quarter Form 10-Q
Liabilities Measured at Fair Value
September 30December 31
20262025
Deferred compensation arrangements$339$307
Level 1 - Liabilities$339$307
Foreign currency exchange forward contracts$98$170
Level 2 - Liabilities$98$170
Contingent consideration:
Beginning$518$452
Additions271123
Change in estimate and foreign exchange1024
Settlements(90)(81)
Ending$709$518
Level 3 - Liabilities$709$518
Total liabilities measured at fair value$1,146$995
Fair Value of Available for Sale Securities by Maturity
September 30December 31
20262025
Due in one year or less$—$41
Due after one year through three years$—$48

The aggregate difference between the cost and fair value of

available-for-sale marketable securities was nominal at

December 31, 2025. Our investments in available-for-sale

marketable securities were sold during the three months ended

September 30, 2026. Interest income on cash and cash

equivalents, short-term investments and income from marketable

securities was $36 and $28 in the three months 2026 and 2025,

and $96 and $90 in the nine months 2026 and 2025, which was

recorded in other income.

Our investments in available-for-sale marketable securities had a

minimum credit quality rating of A2 (Moody's), A (Standard &

Poor's) and A (Fitch).

NOTE 6 - CONTINGENCIES AND COMMITMENTS

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of business, including

proceedings related to product, labor, tax, intellectual property

and other matters. The outcomes of these matters will generally

not be known for prolonged periods of time. In certain of the legal

proceedings the claimants seek damages as well as other

compensatory and equitable relief that could result in the

payment of significant claims and settlements and/or the

imposition of injunctions or other equitable relief. For legal

matters for which management had sufficient information to

reasonably estimate our future obligations, a liability representing

management's best estimate of the probable loss, or the

minimum of the range of probable losses when a best estimate

within the range is not known, is recorded. The estimates are

based on consultation with legal counsel, previous settlement

experience and settlement strategies. If actual outcomes are less

favorable than those estimated by management, additional

expense may be incurred, which could unfavorably affect future

operating results. We are self-insured for certain claims and

expenses. The ultimate cost to us with respect to product liability

claims could be materially different than the amount of the current

estimates and accruals and could have a material adverse effect

on our financial position, results of operations and cash flows.

Leases
September 30December 31
20262025
Right-of-use assets$518$519
Lease liabilities, current$160$153
Lease liabilities, non-current$343$348
Other information:
Weighted-average remaining lease term (years)4.55.0
Weighted-average discount rate3.81%3.77%
Three MonthsNine Months
2026202520262025
Operating lease cost$52$48$161$153

Other Contractual Obligations and Commitments

Our outstanding balances of confirmed invoices in the supplier

financing program were $88 and $75 at September 30, 2026 and

December 31, 2025 and are included within accounts payable in

our Consolidated Balance Sheets.

NOTE 7 - ACQUISITIONS

We acquire stock in companies and various assets that continue

to support our capital deployment and product development

strategies. In the nine months 2026 and 2025 cash paid for

acquisitions, net of cash acquired was $481 and $4,950.

In May 2026 we completed the acquisition of AVS for net cash

consideration of $434 and up to $400 in future milestone

payments that had a fair value of $271 at the acquisition date.

AVS is developing a next-generation intravascular lithotripsy

platform designed to treat complex peripheral arterial disease.

AVS is part of our Peripheral Vascular business within MedSurg

and Neurotechnology. Acquired in-process research and

development intangible assets represent projects where the

related product has not yet received regulatory approval. The

purchase price allocation for AVS is based on preliminary

valuations, primarily related to in-process research and

development. Goodwill attributable to the acquisition reflects the

strategic benefits of expanding our peripheral vascular portfolio.

This goodwill is not deductible for tax purposes.

In February 2025 we completed the acquisition of Inari for $80

per share, or an aggregate purchase price of $4,810, net of cash

acquired. Inari's product portfolio includes minimally invasive

products for the treatment of venous thromboembolism. Inari is

part of our Peripheral Vascular business within MedSurg and

Neurotechnology. Goodwill attributable to the acquisition reflects

the strategic benefits of expanding our market presence,

diversifying our product portfolio and advancing innovations. This

goodwill is not deductible for tax purposes. Share-based awards

for Inari employees vested upon our acquisition and a charge of

$139 was recorded in selling, general and administrative

expenses in the nine months 2025.

Dollar amounts are in millions except per share amounts or as otherwise specified.9
STRYKER CORPORATION2026 Third Quarter Form 10-Q

The purchase price allocations for AVS and Inari are:

Purchase Price Allocation of Acquired Net Assets
20262025
AVSInari
Tangible assets acquired:
Accounts receivable$—$78
Inventory—215
Deferred income tax assets3134
Other assets1484
Deferred income tax liabilities(98)(489)
Other liabilities(14)(189)
Intangible assets:
Developed technologies—1,458
In-process research and development402—
Customer relationships—330
Other intangibles—72
Goodwill3983,117
Purchase price, net of cash acquired of $10 and $64$705$4,810
Weighted average amortization period at acquisition (years):
Developed technologies—13
Customer relationships—13
Other intangibles—9

Consolidated estimated annual amortization expense for definite-

lived intangible assets is:

Remainder of 20262027202820292030
$175$682$634$618$600

NOTE 8 - DEBT AND CREDIT FACILITIES

We have lines of credit issued by various financial institutions that

are available to fund our day-to-day operating needs. Certain of

our credit facilities require us to comply with financial and other

covenants. We were in compliance with all covenants on

September 30, 2026.

On September 30, 2026 we had $250 outstanding under our

commercial paper programs which allow for maturities up to 397

days from the date of issuance. The maximum amount of our

commercial paper that can be outstanding at any time is $3,000.

In March 2026 we repaid $1,000 of 3.500% senior unsecured

notes. The following table summarizes our total debt at

September 30:

Summary of Total Debt
September 30December 31
RateDue20262025
Senior unsecured notes:
3.500%March 15, 2026—1,000
4.550%February 10, 2027499498
2.125%November 30, 2027850881
4.700%February 10, 2028698697
3.650%March 7, 2028599599
4.850%December 8, 2028597597
3.375%December 11, 2028679704
0.750%March 1, 2029906939
4.250%September 11, 2029746744
4.850%February 10, 2030795794
1.950%June 15, 2030995995
2.625%November 30, 2030733759
1.000%December 3, 2031846876
3.375%September 11, 2032901934
4.625%September 11, 2034742741
5.200%February 10, 2035991990
3.625%September 11, 2036671695
4.100%April 1, 2043393393
4.375%May 15, 2044396396
4.625%March 15, 2046985984
2.900%June 15, 2050643643
Commercial paper250—
Other15—
Total debt$14,930$15,859
Less current maturities7541,000
Total long-term debt$14,176$14,859
September 30December 31
20262025
Unamortized debt issuance costs$60$70
Borrowing capacity on existing facilities$2,664$2,911
Fair value of senior unsecured notes$13,499$15,344

The fair value of the senior unsecured notes was estimated using

quoted interest rates, maturities and amounts of borrowings

based on quoted active market prices and yields that took into

account the underlying terms of the debt instruments.

Substantially all of our debt is classified within Level 2 of the fair

value hierarchy.

Interest expense on outstanding debt and credit facilities,

including required fees incurred totaled $137 and $157 for the

three months 2026 and 2025 and $415 and $453 for the nine

months 2026 and 2025.

NOTE 9 - INCOME TAXES

Our effective tax rates were 24.5% and 18.7% in the three and

nine months 2026 and 16.5% and 14.7% in the three and nine

months 2025. The effective tax rate for the three months 2026

increased from the three months 2025 due to the 2026 non-

deductible goodwill impairment. The effective tax rate for the nine

months 2026 increased from the nine months 2025 due to the

2026 non-deductible goodwill impairment and the 2025 tax

benefit related to the sale of the Spinal Implants business. The

effective tax rates for the three and nine months 2026 and 2025

reflect the continued lower effective income tax rates as a result

of our European operations and certain discrete tax items.

Income tax authorities in various jurisdictions globally conduct

routine audits of our income tax returns to determine if they agree

with our interpretations of income tax regulations. Any audit

assessment, draft audit assessment or final audit report received

is reviewed for new information and evaluated for proper financial

statement treatment.

Dollar amounts are in millions except per share amounts or as otherwise specified.10
STRYKER CORPORATION2026 Third Quarter Form 10-Q

NOTE 10 - SEGMENT INFORMATION

We segregate our operations into two reportable business

segments: (i) MedSurg and Neurotechnology and (ii)

Orthopaedics which aligns to our internal reporting structure and

how our Chief Operating Decision Maker (CODM) assesses the

performance and allocates resources. The CODM is the Chief

Executive Officer. The CODM makes decisions on resource

allocation, assesses performance of the business, and monitors

budget versus actual results using segment operating income.

Information about total assets by segment is not disclosed

because such information is not regularly provided to, or used by,

our CODM.

Segment Results
Three MonthsNine Months
2026202520262025
MedSurg and Neurotechnology$3,664$3,355$10,496$9,716
Orthopaedics2,8562,7028,6338,229
Net sales$6,520$6,057$19,129$17,945
MedSurg and Neurotechnology$1,367$1,294$4,001$3,732
Orthopaedics8187692,4792,325
Cost of sales$2,185$2,063$6,480$6,057
MedSurg and Neurotechnology$242$229$728$666
Orthopaedics161158470476
Segment research, development and engineering expenses$403$387$1,198$1,142
MedSurg and Neurotechnology$944$902$2,817$2,670
Orthopaedics8557762,5502,445
Segment selling, general and administrative expenses$1,799$1,678$5,367$5,115
MedSurg and Neurotechnology$59$56$179$170
Orthopaedics131123389353
Segment depreciation and amortization$190$179$568$523
Corporate and Other$32$34$98$87
Amortization of intangible assets175189530543
Total depreciation and amortization$397$402$1,196$1,153
MedSurg and Neurotechnology$1,052$874$2,771$2,478
Orthopaedics8918762,7452,630
Segment operating income$1,943$1,750$5,516$5,108
Items not allocated to segments:
Corporate and Other$(237)$(200)$(732)$(669)
Inventory stepped up to fair value—(61)—(160)
Acquisition and integration-related charges(17)(39)(61)(302)
Amortization of intangible assets(175)(189)(530)(543)
Structural optimization and other special charges(153)(41)(366)(93)
Goodwill and other impairments(293)(73)(294)(163)
Medical device regulation(6)(11)(16)(30)
Recall-related matters4(1)(8)(56)
Regulatory and legal matters(32)—(38)(7)
Reversal of 2025 tariffs——158—
Consolidated operating income$1,034$1,135$3,629$3,085
Segment Capital SpendingNine Months
20262025
Purchases of property, plant and equipment:
MedSurg and Neurotechnology$196$134
Orthopaedics208188
Total segment purchases of property, plant and equipment$404$322
Corporate and Other201171
Total purchases of property, plant and equipment$605$493

NOTE 11 - GOODWILL AND OTHER INTANGIBLE ASSETS

We test goodwill annually for impairment at October 31 or

whenever events or circumstances indicate that goodwill may be

impaired. During the third quarter 2026, various factors indicated

it was more likely than not that the carrying value of our

Peripheral Vascular reporting unit exceeded its fair value. As a

result, we performed an interim impairment assessment of

goodwill, indefinite-lived and other long-lived assets of the

Peripheral Vascular reporting unit and a charge of $293 was

recognized in goodwill and other impairments in the Consolidated

Statements of Earnings. The impairment amount represents the

excess of the carrying value of the Peripheral Vascular reporting

unit over its fair value, which we estimated using an income-

based valuation approach.

The impairment charge for the Peripheral Vascular reporting unit

was primarily driven by a reduction in forecasted cash flows

reflecting near-term operational and supply constraints and a

longer expected period to achieve anticipated growth and market

recovery. Significant inputs to the analysis included assumptions

for future revenue growth, operating margin, the effective tax rate

applied to future earnings and the rate used to discount the

estimated future cash flows to their present value, based on the

reporting unit’s estimated weighted average cost of capital.

Future changes in the judgments, assumptions and estimates

that are used in our impairment testing for goodwill, including

discount and tax rates and future cash flow projections, could

result in significantly different estimates of the fair values. A

significant reduction in the estimated fair values could result in

impairment charges that could materially affect our results of

operations.

In the first quarter 2026 we changed our organizational structure

as further described in Note 1. Following this reorganization we

continue to have two reportable segments, MedSurg and

Neurotechnology and Orthopaedics. The reorganization impacts

the composition of the Instruments and Joint Replacement

reporting units and results in a new reporting unit representing

the Ortho Tech business.

In connection with this reorganization we reallocated the goodwill

associated with the impacted businesses using the relative fair

value approach, resulting in a reallocation of $518 of goodwill

from the MedSurg and Neurotechnology segment to the

Orthopaedics segment.

NOTE 12 - SUBSEQUENT EVENTS

In October 2026 we signed an agreement with CMR Surgical, a

global robotics company and maker of the Versius Plus surgical

robot, to invest approximately $400 in cash in exchange for CMR

Surgical's preferred equity. The agreement grants us exclusive

U.S. distribution rights for the Versius portfolio and an exclusive

option to acquire 100% of CMR Surgical's remaining outstanding

equity in the future. The transaction is expected to close in the

fourth quarter 2026, subject to regulatory approval and customary

closing conditions.

In October 2026 our Board of Directors approved an increase of

$3,000 to our existing share repurchase program, bringing the

total share repurchase authorization to $3,033. The manner,

timing and amount of repurchases are determined by

management based on an evaluation of market conditions, stock

price, and other factors and are subject to regulatory

considerations. Purchases may be made from time to time in the

open market, in privately negotiated transactions or otherwise.

Dollar amounts are in millions except per share amounts or as otherwise specified.11
STRYKER CORPORATION2026 Third Quarter Form 10-Q

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ABOUT STRYKER

Stryker Corporation ("we" or the "Company") is a global leader in

medical technologies and, together with our customers, we are

driven to make healthcare better. We offer innovative products

and services in MedSurg, Neurotechnology, and Orthopaedics

that help improve patient and healthcare outcomes. Alongside

our customers around the world, we impact more than 150 million

patients annually. Our goal is to achieve sales growth at the high-

end of the medical technology (MedTech) industry and maintain

our long-term capital allocation strategy that prioritizes: (1)

Acquisitions, (2) Dividends and (3) Share repurchases.

MedSurg and Neurotechnology products include surgical

equipment, patient and caregiver safety technologies, and a

comprehensive line of products for traditional brain and open

skull-based surgical procedures orthobiologic and biosurgery

products, including synthetic bone grafts and vertebral

augmentation (Instruments), endoscopic and communications

systems (Endoscopy), patient handling, emergency medical

equipment, intensive care disposable products, clinical

communication and artificial intelligence-assisted virtual care

platform technology (Medical), and minimally invasive products

for the treatment of acute ischemic and hemorrhagic stroke and

venous thromboembolism (Vascular). Orthopaedics products

include implants and surgical equipment such as navigation

systems and robotics used in total joint replacements, such as

hip, knee and shoulder, ankle and trauma and extremities

surgeries. We bring patients and physicians advanced implant

designs and specialized instrumentation that make orthopaedic

surgery and recovery simpler, faster and more effective. We

support surgeons with technologies, products and services they

need to support each patient’s clinical challenge.

Overview of the Three and Nine Months

In the three months 2026 we achieved sales growth of 7.7% from

  1. Organic net sales increased 7.7%, primarily driven by

increased unit volume. We reported operating income margin of

15.9%, net earnings of $753 and net earnings per diluted share

of $1.96. Excluding the impact of certain items, adjusted

operating income margin(1) increased by 60 basis points to

26.2%, with adjusted net earnings(1) of $1,357 and adjusted net

earnings per diluted share(1) of $3.52, an increase of 10.3% from

In the nine months 2026 we achieved sales growth of 6.6% from

  1. Excluding the impact of acquisitions and divestitures,

organic net sales increased 6.4%, primarily driven by increased

unit volume. We reported operating income margin of 19.0%, net

earnings of $2,774 and net earnings per diluted share of $7.19.

Excluding the impact of certain items, adjusted operating income

margin(1) increased by 30 basis points to 25.0%, with adjusted

net earnings(1) of $3,785 and adjusted net earnings per diluted

share(1) of $9.81, an increase of 7.1% from 2025.

(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-

GAAP financial measures used in this report and a reconciliation to the

most directly comparable GAAP financial measure.

CONSOLIDATED RESULTS OF OPERATIONS
Three MonthsNine Months
Percent Net SalesPercentagePercent Net SalesPercentage
2026202520262025Change2026202520262025Change
Net sales$6,520$6,057100.0%100.0%7.7%$19,129$17,945100.0%100.0%6.6%
Gross profit4,2483,85265.263.610.312,55611,43765.663.79.8
Research, development and engineering expenses4334106.66.85.61,2801,2226.76.84.7
Selling, general and administrative expenses2,3132,04535.533.813.16,8236,42435.735.86.2
Amortization of intangible assets1751892.73.1(7.4)5305432.83.0(2.4)
Goodwill and other impairments293734.51.2nm2941631.50.9nm
Interest expense(143)(157)(2.2)(2.6)(8.9)(432)(453)(2.3)(2.5)(4.6)
Other income106511.60.8107.82141771.11.020.9
Income taxes244170nmnm43.5637412nmnm54.6
Net earnings$753$85911.5%14.2%(12.3)%$2,774$2,39714.5%13.4%15.7%
Net earnings per diluted share$1.96$2.22(11.7)%$7.19$6.2016.0%
Adjusted net earnings per diluted share**(1)**$3.52$3.1910.3%$9.81$9.167.1%

nm - not meaningful

Dollar amounts are in millions except per share amounts or as otherwise specified.12
STRYKER CORPORATION2026 Third Quarter Form 10-Q
SALES GROWTH ANALYSIS
Three MonthsNine Months
Percentage ChangePercentage Change
20262025As ReportedConstant Currency20262025As ReportedConstant Currency
MedSurg and Neurotechnology:
Instruments
United States$835$7974.8%4.8%$2,441$2,2757.4%7.4%
International1611526.57.147843011.38.8
Total$996$9495.1%5.2%$2,919$2,7058.0%7.6%
Endoscopy
United States$839$74313.0%13.0%$2,359$2,1957.5%7.5%
International18215318.018.553446714.211.4
Total$1,021$89613.9%14.0%$2,893$2,6628.7%8.2%
Medical
United States$910$82710.0%10.0%$2,602$2,4695.4%5.4%
International1711588.18.550345111.48.2
Total$1,081$9859.7%9.8%$3,105$2,9206.3%5.8%
Vascular
United States$320$28313.0%13.0%$850$75412.7%12.7%
International2462422.10.87296758.04.9
Total$566$5258.0%7.4%$1,579$1,42910.5%9.0%
MedSurg and Neurotechnology
United States$2,904$2,6509.6%9.6%$8,252$7,6937.3%7.3%
International7607057.87.72,2442,02310.98.0
Total$3,664$3,3559.2%9.2%$10,496$9,7168.0%7.4%
Orthopaedics:
Knees
United States$458$4521.3%1.3%$1,418$1,3763.0%3.0%
International1771760.51.15805319.36.6
Total$635$6281.1%1.2%$1,998$1,9074.8%4.0%
Hips
United States$277$279(0.6)%(0.6)%$849$8312.2%2.2%
International176178(1.7)(0.8)5435351.4(0.6)
Total$453$457(1.0)%(0.7)%$1,392$1,3661.9%1.1%
Trauma and Extremities
United States$735$7034.5%4.5%$2,293$2,1188.2%8.2%
International2752577.58.482474410.97.9
Total$1,010$9605.3%5.5%$3,117$2,8628.9%8.1%
Ortho Tech
United States$576$48718.1%18.1%$1,573$1,42910.0%10.0%
International1781649.09.554448811.69.3
Total$754$65115.8%16.0%$2,117$1,91710.4%9.8%
$2,852$2,6965.8%6.0%$8,624$8,0527.1%6.4%
Spinal Implants
United States$—$——%—%$—$118(100.0)%(100.0)%
International46(43.9)(45.4)959(85.7)(87.1)
Total$4$6(43.9)%(45.4)%$9$177(95.2)%(95.5)%
Orthopaedics
United States$2,046$1,9216.5%6.5%$6,133$5,8724.4%4.4%
International8107813.84.52,5002,3576.13.5
Total$2,856$2,7025.7%5.9%$8,633$8,2294.9%4.1%
Geographic:
United States$4,950$4,5718.3%8.3%$14,385$13,5656.0%6.0%
International1,5701,4865.76.04,7444,3808.35.6
Total$6,520$6,0577.7%7.7%$19,129$17,9456.6%5.9%

Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the

orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and

the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics were combined with the remaining

Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $535

and $492 and Other Orthopaedics of $219 and $159 for the three months 2026 and 2025. For the nine months 2026 and 2025 Ortho

Tech includes sales related to Orthopaedic Instruments of $1,547 and $1,477 and Other Orthopaedics of $570 and $440. Instruments

includes sales related to Neuro Cranial of $670 and $637 and Enabling Technologies of $28 and $45 for the three months 2026 and

  1. For the nine months 2026 and 2025 Instruments includes sales related to Neuro Cranial of $1,957 and $1,816 and Enabling

Technologies of $82 and $108. We have reflected these changes in all historical periods presented.

Dollar amounts are in millions except per share amounts or as otherwise specified.13
STRYKER CORPORATION2026 Third Quarter Form 10-Q

Consolidated Net Sales

Consolidated net sales increased 7.7% in the three months 2026

on both a reported and constant currency basis. Net sales in

constant currency increased by 7.6% from increased unit volume

and 0.1% due to higher prices. The unit volume increase was due

to higher product shipments across all MedSurg and

Neurotechnology businesses and certain Orthopaedics

businesses.

Consolidated net sales increased 6.6% in the nine months 2026

as reported and 5.9% in constant currency as foreign currency

exchange rates positively impacted net sales by 0.7%. Excluding

the (0.5)% impact of acquisitions and divestitures, net sales in

constant currency increased by 6.2% from increased unit volume

and 0.2% due to higher prices. The unit volume increase was due

to higher product shipments across all MedSurg and

Neurotechnology businesses and most Orthopaedics businesses.

MedSurg and Neurotechnology Net Sales

MedSurg and Neurotechnology net sales increased 9.2% in the

three months 2026 on both a reported and constant currency

basis. Excluding the 0.1% impact of acquisitions and divestitures,

net sales in constant currency increased by 8.9% from increased

unit volume and 0.2% from higher prices. The unit volume

increase was due to higher shipments across all Medsurg and

Neurotechnology businesses.

MedSurg and Neurotechnology net sales increased 8.0% in the

nine months 2026 as reported and 7.4% in constant currency, as

foreign currency exchange rates positively impacted net sales by

0.6%. Excluding the 0.8% impact of acquisitions and divestitures,

net sales in constant currency increased by 6.3% from increased

unit volume and 0.3% from higher prices. The unit volume

increase was due to higher shipments across all MedSurg and

Neurotechnology businesses.

Orthopaedics Net Sales

Orthopaedics net sales increased 5.7% in the three months 2026

as reported and 5.9% in constant currency, as foreign currency

exchange rates negatively impacted net sales by (0.2)%. Net

sales in constant currency increased 5.9% from increased unit

volume. The unit volume increase was due to higher shipments

primarily within the Ortho Tech and Trauma and Extremities

businesses.

Orthopaedics net sales increased 4.9% in the nine months 2026

as reported and 4.1% in constant currency, as foreign currency

exchange rates positively impacted net sales by 0.8%. Excluding

the (2.1)% impact of acquisitions and divestitures, net sales in

constant currency increased 6.2% from increased unit volume.

The unit volume increase was due to higher shipments across

most Orthopaedics businesses.

Gross Profit

Gross profit was $4,248 and $3,852 in the three months 2026

and 2025. The key components of the change were:

Gross Profit Percent Net Sales
Three Months 202563.6%
Volume and mix60 bps
Manufacturing and supply chain costs(20) bps
Structural optimization and other special charges20 bps
Inventory stepped up to fair value100 bps
Three Months 202665.2%

Gross profit as a percentage of net sales in the three months

2026 increased to 65.2% from 63.6% in 2025 primarily driven by

lower amortization of inventory stepped up to fair value.

Gross profit was $12,556 and $11,437 in the nine months 2026

and 2025. The key components of the change were:

Gross Profit Percent Net Sales
Nine Months 202563.7%
Sales pricing10 bps
Volume and mix50 bps
Manufacturing and supply chain costs(80) bps
Structural optimization and other special charges30 bps
Inventory stepped up to fair value90 bps
Reversal of 2025 tariffs90 bps
Nine Months 202665.6%

Gross profit as a percentage of net sales in the nine months 2026

increased to 65.6% from 63.7% in 2025 driven by a reduction of

certain import tariffs and lower amortization of inventory stepped

up to fair value partially offset by higher manufacturing and

supply chain costs primarily due to idle production time related to

the cybersecurity incident in the first quarter 2026.

While segment mix was not a significant driver of the change in

gross profit as a percent of net sales between the nine months

2026 and 2025, we generally expect segment mix to have an

unfavorable impact for the foreseeable future as we anticipate

more rapid sales growth in our lower gross margin MedSurg and

Neurotechnology segment than our Orthopaedics segment.

Research, Development and Engineering Expenses

Research, development and engineering expenses increased

$23 or 5.6% in the three months 2026 and $58 or 4.7% in the

nine months 2026. Expenses as a percentage of net sales of

6.6% in the three months and 6.7% in the nine months 2026

remained relatively flat with 6.8% in the three and nine months

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $268 or

13.1% in the three months 2026. As a percentage of net sales,

expenses increased to 35.5% from 33.8% in 2025, primarily due

to higher structural optimization and other special charges.

Selling, general and administrative expenses increased $399 or

6.2% in the nine months 2026. Expenses as a percentage of net

sales of 35.7% remained relatively flat with 35.8% in 2025.

Higher structural optimization and other special charges in the

nine months 2026 were offset by lower acquisition and

integration-related costs.

Amortization of Intangible Assets

Amortization of intangible assets was $175 and $189 in the three

months and $530 and $543 in the nine months 2026 and 2025.

Refer to Note 7 to our Consolidated Financial Statements for

further information.

Goodwill and Other Impairments

We recorded a goodwill impairment charge of $293 in the three

months 2026 related to our Peripheral Vascular business. Refer

to Note 11 to our Consolidated Financial Statements for further

information.

We recorded other impairments of $73 in the three months 2025

and $1 and $163 in the nine months 2026 and 2025.

Operating Income

Operating income was $1,034 and $1,135 in the three months

2026 and 2025. Operating income as a percentage of net sales in

the three months 2026 decreased to 15.9% from 18.7% in 2025.

Refer to the discussion above for the primary drivers of the

change.

Dollar amounts are in millions except per share amounts or as otherwise specified.14
STRYKER CORPORATION2026 Third Quarter Form 10-Q

Operating income was $3,629 and $3,085 in the nine months

2026 and 2025. Operating income as a percentage of net sales in

the nine months 2026 increased to 19.0% from 17.2% in 2025.

Refer to the discussion above for the primary drivers of the

change.

MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 28.7% in the three months

2026 from 26.1% in 2025. Orthopaedics operating income as a

percentage of net sales decreased to 31.2% in the three months

2026 from 32.4% in 2025. The key components of the change

were:

Operating Income Percent Net Sales
MedSurg and NeurotechnologyOrthopaedics
Three Months 202526.1%32.4%
Sales pricing10 bps0 bps
Volume70 bps40 bps
Manufacturing and supply chain costs50 bps(70) bps
Research, development and engineering expenses20 bps20 bps
Selling, general and administrative expenses110 bps(110) bps
Three Months 202628.7%31.2%

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales for the three months was primarily

driven by lower selling, general and administrative expenses,

lower manufacturing and supply chain costs and higher unit

volumes.

The decrease in Orthopaedics operating income as a percentage

of net sales for the three months was primarily driven by higher

selling, general and administrative expenses and higher

manufacturing and supply chain costs, partially offset by higher

unit volumes.

MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 26.4% in the nine months

2026 from 25.5% in 2025. Orthopaedics operating income as a

percentage of net sales decreased to 31.8% in the nine months

2026 from 32.0% in 2025. The key components of the change

were:

Operating Income Percent Net Sales
MedSurg and NeurotechnologyOrthopaedics
Nine Months 202525.5%32.0%
Sales pricing10 bps0 bps
Volume50 bps30 bps
Manufacturing and supply chain costs(20) bps(90) bps
Research, development and engineering expenses(10) bps30 bps
Selling, general and administrative expenses60 bps10 bps
Nine Months 202626.4%31.8%

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales for the nine months was primarily

driven by lower selling, general and administrative expenses and

higher unit volumes, partially offset by higher manufacturing and

supply chain costs and higher research, development and

engineering expenses.

The decrease in Orthopaedics operating income as a percentage

of net sales for the nine months was primarily driven by higher

manufacturing and supply chain costs, partially offset by lower

research, development and engineering expenses, lower selling,

general and administrative expenses and higher unit volumes.

Interest Expense

Interest expense was $143 and $157 in the three months and

$432 and $453 in the nine months 2026 and 2025. The decrease

in interest expense in the three and nine months 2026 from 2025

was due to lower outstanding debt and credit facilities partially

offset by higher average interest rates.

Other Income

Other income was $106 and $51 in the three months and $214

and $177 in the nine months 2026 and 2025. The increase in

other income in the three and nine months 2026 from 2025 was

primarily due to income from intellectual property licensing in

Income Taxes

Our effective tax rates were 24.5% and 18.7% in the three and

nine months 2026 and 16.5% and 14.7% in the three and nine

months 2025. The effective tax rate for the three months 2026

increased from the three months 2025 due to the 2026 non-

deductible goodwill impairment. The effective tax rate for the nine

months 2026 increased from the nine months 2025 due to the

2026 non-deductible goodwill impairment and the 2025 tax

benefit related to the sale of the Spinal Implants business. The

effective tax rates for the three and nine months 2026 and 2025

reflect the continued lower effective income tax rates as a result

of our European operations and certain discrete tax items.

Our future results of operations could be affected by changes in

the effective tax rate as a result of changes in tax laws,

regulations and judicial rulings. We are continuing to evaluate the

impact of tax reform in the countries in which we operate as new

guidance is published and new regulations are adopted.

Net Earnings

Net earnings decreased to $753 or $1.96 per diluted share in the

three months 2026 from $859 or $2.22 per diluted share in 2025.

Net earnings increased to $2,774 or $7.19 per diluted share in

the nine months 2026 from $2,397 or $6.20 per diluted share in

  1. Refer to the discussion above for the primary drivers of the

change.

Non-GAAP Financial Measures

We supplement the reporting of our financial information

determined under accounting principles generally accepted in the

United States (GAAP) with certain non-GAAP financial measures,

including percentage sales growth in constant currency;

percentage organic sales growth; adjusted gross profit; adjusted

selling, general and administrative expenses; adjusted research,

development and engineering expenses; adjusted operating

income; adjusted other income (expense), net; adjusted income

taxes; adjusted effective income tax rate; adjusted net earnings;

and adjusted net earnings per diluted share (Diluted EPS). We

believe these non-GAAP financial measures provide meaningful

information to assist investors and shareholders in understanding

our financial results and assessing our prospects for future

performance. Management believes percentage sales growth in

constant currency and the other adjusted measures described

above are important indicators of our operations because they

exclude items that may not be indicative of or are unrelated to our

core operating results and provide a baseline for analyzing trends

in our underlying businesses. Management uses these non-

GAAP financial measures for reviewing the operating results of

reportable business segments and analyzing potential future

business trends in connection with our budget process and bases

certain management incentive compensation on these non-GAAP

financial measures. To measure percentage sales growth in

Dollar amounts are in millions except per share amounts or as otherwise specified.15
STRYKER CORPORATION2026 Third Quarter Form 10-Q

constant currency, we remove the impact of changes in foreign

currency exchange rates that affect the comparability and trend

of sales. Percentage sales growth in constant currency is

calculated by translating current and prior year results at the

same foreign currency exchange rate. To measure percentage

organic sales growth, we remove the impact of changes in

foreign currency exchange rates, acquisitions and divestitures,

which affect the comparability and trend of sales. Percentage

organic sales growth is calculated by translating current year and

prior year results at the same foreign currency exchange rates

excluding the impact of acquisitions and divestitures. To measure

earnings performance on a consistent and comparable basis, we

exclude certain items that affect the comparability of operating

results and the trend of earnings. The income tax effect of each

adjustment was determined based on the tax effect of the

jurisdiction in which the related pre-tax adjustment was recorded.

These adjustments are irregular in timing and may not be

indicative of our past and future performance. The following are

examples of the types of adjustments that may be included in a

period:

1.Acquisition and integration-related costs. Costs related to

integrating recently acquired businesses (e.g., costs

associated with the termination of sales relationships,

employee retention and workforce reductions, manufacturing

integration costs and other integration-related activities),

changes in the fair value of contingent consideration,

amortization of inventory stepped-up to fair value, specific

costs (e.g., deal costs and costs associated with legal entity

rationalization) related to the consummation of the

acquisition process and legal entity rationalization and

acquisition-related tax items.

2.Amortization of purchased intangible assets. Periodic

amortization expense related to purchased intangible assets.

3.Structural optimization and other special charges. Costs

associated with employee retention and workforce

reductions, the closure or transfer of manufacturing and

other facilities (e.g., site closure costs, contract termination

costs and redundant employee costs during the work

transfers), product line exits (primarily inventory, long-lived

asset and specifically-identified intangible asset write-offs),

certain long-lived and intangible asset write-offs and

impairments and other charges.

4.Medical device regulations. Costs specific to updating our

quality system, product labeling, asset write-offs and product

remanufacturing to comply with the new medical device

reporting regulations and other requirements of the

European Union.

5.Recall-related matters. Changes in our best estimate of the

probable loss, or the minimum of the range of probable

losses when a best estimate within a range is not known, to

resolve the Rejuvenate, LFIT V40, Wright legacy hip

products and other product recalls.

6.Regulatory and legal matters. Changes in our best estimate

of the probable loss, or the minimum of the range of

probable losses when a best estimate within a range is not

known, to resolve certain regulatory or other legal matters

and the amount of favorable awards from settlements.

7.Tax matters. Impact of accounting for certain significant and

discrete tax items.

Because non-GAAP financial measures are not standardized, it

may not be possible to compare these financial measures with

other companies' non-GAAP financial measures having the same

or similar names. These adjusted financial measures should not

be considered in isolation or as a substitute for reported sales

growth, gross profit, selling, general and administrative expenses,

research, development and engineering expenses, operating

income, other income (expense), net, income taxes, effective

income tax rate, net earnings and net earnings per diluted share,

the most directly comparable GAAP financial measures. These

non-GAAP financial measures are an additional way of viewing

aspects of our operations when viewed with our GAAP results

and the reconciliations to corresponding GAAP financial

measures at the end of the discussion of Consolidated Results of

Operations below. We strongly encourage investors and

shareholders to review our financial statements and publicly-filed

reports in their entirety and not to rely on any single financial

measure.

The weighted-average diluted shares outstanding used in the

calculation of adjusted net earnings per diluted share are the

same as those used in the calculation of reported net earnings

per diluted share for the respective period.

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective Tax RateDiluted EPS
Reported$4,248$2,313$433$1,034$(37)$244$75324.5%$1.96
Reported percent net sales65.2%35.5%6.6%15.9%(0.6)%nm11.5%
Acquisition and integration-related costs:
Inventory stepped-up to fair value—————————
Other acquisition and integration-related (a)6(5)(6)17—314—0.04
Amortization of purchased intangible assets———175—331420.50.37
Structural optimization and other special charges (b)12(137)(4)153(54)23760.80.20
Goodwill and other impairments (c)———293——293(4.8)0.76
Medical device regulations (d)——(6)6—15—0.01
Recall-related matters (e)—4—(4)—(2)(2)(0.1)—
Regulatory and legal matters (f)—(32)—32—6260.10.07
Tax matters (g)—————(50)50(5.0)0.11
Reversal of 2025 tariffs—————————
Adjusted$4,266$2,143$417$1,706$(91)$258$1,35716.0%$3.52
Adjusted percent net sales65.4%32.8%6.4%26.2%(1.4)%nm20.8%
Dollar amounts are in millions except per share amounts or as otherwise specified.16
STRYKER CORPORATION2026 Third Quarter Form 10-Q
Three Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective Tax RateDiluted EPS
Reported$3,852$2,045$410$1,135$(106)$170$85916.5%$2.22
Reported percent net sales63.6%33.8%6.8%18.7%(1.8)%nm14.2%
Acquisition and integration-related costs:
Inventory stepped-up to fair value61——61—15460.60.12
Other acquisition and integration-related (a)5(33)(1)39—6330.10.08
Amortization of purchased intangible assets———189—391501.20.39
Structural optimization and other special charges (b)15(26)—41(10)328(0.1)0.07
Goodwill and other impairments (c)———73—15580.40.16
Medical device regulations (d)——(11)11—380.10.02
Recall-related matters (e)—(1)—1——1——
Regulatory and legal matters (f)—————————
Tax matters (g)—————(50)50(4.8)0.13
Adjusted$3,933$1,985$398$1,550$(116)$201$1,23314.0%$3.19
Adjusted percent net sales65.0%32.8%6.6%25.6%(1.9)%nm20.4%

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

Three Months
20262025
Termination of sales relationships$1$—
Employee retention and workforce reductions111
Changes in the fair value of contingent consideration112
Manufacturing integration costs177
Other integration-related activities(3)9
Adjustments to Operating Income$17$39
Adjustments to Income Taxes$3$6
Adjustments to Net Earnings$14$33

(b) Structural optimization and other special charges represent the costs associated with:

Three Months
20262025
Employee retention and workforce reductions$7$6
Closure/transfer of manufacturing and other facilities88
Product line exits(5)9
Termination of sales relationships in certain countries372
Spinal Implants sale related779
Other charges297
Adjustments to Operating Income$153$41
Adjustments to Other Income (Expense), Net$(54)$(10)
Adjustments to Income Taxes$23$3
Adjustments to Net Earnings$76$28

(c) Goodwill and other impairments represent the costs associated with:

Three Months
20262025
Goodwill impairment$293$—
Certain long-lived and intangible asset write-offs and impairments—22
Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)—51
Adjustments to Operating Income$293$73
Adjustments to Income Taxes$—$15
Adjustments to Net Earnings$293$58

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device

reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

Dollar amounts are in millions except per share amounts or as otherwise specified.17
STRYKER CORPORATION2026 Third Quarter Form 10-Q

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

Three Months
20262025
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$(56)$(61)
Other tax matters611
Adjustments to Income Taxes$(50)$(50)
Adjustments to Other Income (Expense), Net$—$—
Adjustments to Net Earnings$50$50
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Nine Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective Tax RateDiluted EPS
Reported$12,556$6,823$1,280$3,629$(218)$637$2,77418.7%$7.19
Reported percent net sales65.6%35.7%6.7%19.0%(1.1)%nm14.5%
Acquisition and integration-related costs:
Inventory stepped-up to fair value—————————
Other acquisition and integration-related (a)15(32)(14)61—1051—0.14
Amortization of purchased intangible assets———530—964340.41.12
Structural optimization and other special charges (b)31(330)(5)366(71)682270.60.59
Goodwill and other impairments (c)———294——294(1.3)0.76
Medical device regulations (d)——(16)16—313—0.03
Recall-related matters (e)—(8)—8—17—0.02
Regulatory and legal matters (f)—(38)—38—731—0.08
Tax matters (g)—————(87)87(2.6)0.22
Reversal of 2025 tariffs(158)——(158)—(25)(133)—(0.34)
Adjusted$12,444$6,415$1,245$4,784$(289)$710$3,78515.8%$9.81
Adjusted percent net sales65.1%33.5%6.5%25.0%(1.5)%nm19.8%
Nine Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective Tax RateDiluted EPS
Reported$11,437$6,424$1,222$3,085$(276)$412$2,39714.7%$6.20
Reported percent net sales63.7%35.8%6.8%17.2%(1.5)%nm13.4%
Acquisition and integration-related costs:
Inventory stepped-up to fair value160——160—391210.50.31
Other acquisition and integration-related (a)19(280)(3)302—32270(0.4)0.70
Amortization of purchased intangible assets———543—1124311.21.11
Structural optimization and other special charges (b)43(47)(3)93(19)15590.20.15
Goodwill and other impairments (c)———163—461170.80.32
Medical device regulations (d)1—(29)30—7230.10.06
Recall-related matters (e)52(4)—56—947—0.12
Regulatory and legal matters (f)—(7)—7—25—0.01
Tax matters (g)—————(71)71(2.5)0.18
Adjusted$11,712$6,086$1,187$4,439$(295)$603$3,54114.6%$9.16
Adjusted percent net sales65.3%33.9%6.6%24.7%(1.6)%nm19.7%

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

Nine Months
20262025
Termination of sales relationships$7$—
Employee retention and workforce reductions156
Changes in the fair value of contingent consideration1013
Manufacturing integration costs2714
Stock compensation payments upon a change in control—139
Other integration-related activities1680
Adjustments to Operating Income$61$302
Adjustments to Income Taxes$10$32
Adjustments to Net Earnings$51$270
Dollar amounts are in millions except per share amounts or as otherwise specified.18
STRYKER CORPORATION2026 Third Quarter Form 10-Q

(b) Structural optimization and other special charges represent the costs associated with:

Nine Months
20262025
Employee retention and workforce reductions$20$36
Closure/transfer of manufacturing and other facilities1720
Product line exits62
Termination of sales relationships in certain countries124(2)
Spinal Implants sale related12817
Other charges7120
Adjustments to Operating Income$366$93
Adjustments to Other Income (Expense), Net$(71)$(19)
Adjustments to Income Taxes$68$15
Adjustments to Net Earnings$227$59

(c) Goodwill and other impairments represent the costs associated with:

Nine Months
20262025
Goodwill impairment$293$—
Certain long-lived and intangible asset write-offs and impairments—108
Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)155
Adjustments to Operating Income$294$163
Adjustments to Income Taxes$—$46
Adjustments to Net Earnings$294$117

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device

reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

Nine Months
20262025
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$(131)$(153)
Other tax matters4482
Adjustments to Income Taxes$(87)$(71)
Adjustments to Other Income (Expense), Net$—$—
Adjustments to Net Earnings$87$71

FINANCIAL CONDITION AND LIQUIDITY

Nine Months
Net cash provided by (used in):20262025
Operating activities$3,303$2,901
Investing activities(1,011)(4,561)
Financing activities(2,998)1,206
Effect of exchange rate changes(34)58
Change in cash and cash equivalents$(740)$(396)

Operating Activities

Cash provided by operating activities was $3,303 and $2,901 in

the nine months 2026 and 2025. The increase was primarily due

to higher net earnings partially offset by changes in working

capital.

Investing Activities

Cash used in investing activities was $1,011 and $4,561 in the

nine months 2026 and 2025. The nine months 2026 included

cash paid for purchases of property, plant and equipment as well

as for the net cash consideration paid to complete the acquisition

of AVS. The nine months 2025 included cash paid to acquire Inari

and purchases of property, plant and equipment partially offset by

proceeds from the sale of short-term investments. Refer to Note

7 to our Consolidated Financial Statements for further information

on acquisitions.

Financing Activities

Cash used in financing activities was $2,998 in the nine months

2026 and cash provided by financing activities was $1,206 in the

nine months 2025. In 2026 cash used was primarily driven by

repayments of $1,000 to pay off maturing unsecured notes as

described in Note 8 to our Consolidated Financial Statements,

$1,000 repurchases of common stock and dividend payments.

Cash provided by financing activities in 2025 was primarily driven

by proceeds from the issuance of various senior unsecured notes

partially offset by dividend payments.

Liquidity

Cash, cash equivalents, short-term investments and marketable

securities were $3,271 and $4,100 on September 30, 2026 and

December 31, 2025. Current assets exceeded current liabilities

by $7,683 and $6,961 on September 30, 2026 and December 31,

  1. We anticipate being able to support our short-term liquidity

and operating needs from a variety of sources including cash

from operations, commercial paper and existing credit lines.

We have raised funds in the capital markets and have accessed

the credit markets in the past and may continue to do so from

time-to-time. We continue to have strong investment-grade short-

term and long-term debt ratings that we believe should enable us

to refinance our debt as needed.

Our cash, cash equivalents, short-term investments and

marketable securities held in locations outside the United States

Dollar amounts are in millions except per share amounts or as otherwise specified.19
STRYKER CORPORATION2026 Third Quarter Form 10-Q

was approximately 44% on September 30, 2026 compared to

20% on December 31, 2025.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There were no changes to our critical accounting policies and

estimates from those disclosed in our Annual Report on Form 10-

K for 2025, except as follows:

We test goodwill annually for impairment at October 31 or

whenever events or circumstances indicate that goodwill may be

impaired. When it is unlikely that goodwill of a reporting unit is

impaired, we perform a qualitative assessment that may be

periodically supplemented with a corroborative quantitative

analysis.

The Peripheral Vascular business’s operating results have been

affected by a reduction in forecasted cash flows reflecting near-

term operational and supply constraints and a longer expected

period to achieve anticipated growth and market recovery. These

inputs were included in the updated projections used in our

annual long-range financial plan, which was approved during the

third quarter 2026. As a result of these factors, we performed an

interim impairment assessment of goodwill, indefinite-lived and

other long-lived assets of the Peripheral Vascular reporting unit

and a charge of $293 was recognized in goodwill and other

impairments in the Consolidated Statements of Earnings.

Goodwill attributable to the Peripheral Vascular reporting unit was

approximately $3,259 at September 30, 2026.

In our interim quantitative goodwill impairment test, the fair value

of our Peripheral Vascular reporting unit was determined using a

discounted cash flow analysis, which is a form of the income

approach. Significant inputs to the analysis included assumptions

for future revenue growth, operating margin, the effective tax rate

applied to future earnings and the rate used to discount the

estimated future cash flows to their present value based on the

reporting unit’s estimated weighted average cost of capital. Our

assumptions for revenue growth and operating margin

considered several operating factors, including supply constraints

and our competitive environment. We believe our estimates are

appropriate based upon current and future market conditions and

the best information available at the impairment assessment

date; however, future impairment charges could be required if our

Peripheral Vascular reporting unit does not achieve its cash flow,

revenue and profitability projections or if there is an increase in

the weighted average cost of capital.

The assumptions used in the discounted cash flow analysis are

subject to inherent uncertainties and subjectivity. The use of

different assumptions, estimates or judgments with respect to the

estimation of future cash flows and the determination of the

discount rate used to reduce such estimated future cash flows to

their net present value could materially affect the determination of

any impairment charges. Hypothetical changes in our estimates

of the discount rate, long-term revenue growth and long-term

operating margin would result in incremental impairment charges

as follows:

Change in selected assumptionPercentage decline in fair valueIncremental impairment charge
100 bps increase in discount rate15%$823
100 bps decrease in long-term revenue growth3145
100 bps decrease in long-term operating margin9497

Refer to Note 11 to our Consolidated Financial Statements for

discussion on the impact of changes to our organizational

structure in the first quarter 2026 on our reportable segments and

the related goodwill.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing

arrangements, including variable interest entities, of a magnitude

that we believe could have a material impact on our financial

condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of our business, including

proceedings related to product, labor, tax, intellectual property

and other matters. Refer to Note 6 to our Consolidated Financial

Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements that are not historical facts and

are considered "forward-looking statements" within the meaning

of the Private Securities Litigation Reform Act of 1995. These

statements are based on current projections about operations,

industry conditions, financial condition and liquidity. Words that

identify forward-looking statements include, without limitation,

words such as "may," "could," "will," "should," "possible," "plan,"

"predict," "forecast," "potential," "anticipate," "estimate," "expect,"

"project," "intend," "believe," "may impact," "on track," "goal,"

"strategy" and words and terms of similar substance used in

connection with any discussion of future operating or financial

performance, an acquisition or our businesses. In addition, any

statements that refer to expectations, projections or other

characterizations of future events or circumstances, including any

underlying assumptions, are forward-looking statements. Those

statements are not guarantees and are subject to risks,

uncertainties and assumptions that are difficult to predict,

including uncertainties related to the impact of the cybersecurity

incident first reported on March 11, 2026 on our operations and

financial results. Therefore, actual results could differ materially

and adversely from these forward-looking statements, historical

experience or our present expectations. Some important factors

that could cause our actual results to differ from our expectations

in any forward-looking statements include the risks discussed in

Item 1A. "Risk Factors" of our Annual Report on Form 10-K for

  1. This Form 10-Q should be read in conjunction with our

Consolidated Financial Statements and accompanying notes to

our Consolidated Financial Statements in our Annual Report on

Form 10-K for 2025. While we believe that the assumptions

underlying such forward-looking statements are reasonable,

there can be no assurance that future events or developments

will not cause such statements to be inaccurate. All forward-

looking statements contained in this report are qualified in their

entirety by this cautionary statement. We expressly disclaim any

intention or obligation to publicly update or revise any forward-

looking statement to reflect any change in our expectations or in

events, conditions or circumstances on which those expectations

may be based, or that affect the likelihood that actual results will

differ from those contained in the forward-looking statements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We consider our greatest potential area of market risk exposure

to be exchange rate risk on our operating results. Quantitative

and qualitative disclosures about exchange rate risk are included

in Item 7A "Quantitative and Qualitative Disclosures About Market

Risk" of our Annual Report on Form 10-K for 2025. There were

no material changes from the information provided therein.

Dollar amounts are in millions except per share amounts or as otherwise specified.20
STRYKER CORPORATION2026 Third Quarter Form 10-Q

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Chief Executive

Officer and Chief Financial Officer (the Certifying Officers),

evaluated the effectiveness of the Company's disclosure controls

and procedures (as defined in Rules 13a-15(e) or 15d-15(e)

promulgated under the Securities Exchange Act of 1934, as

amended) on September 30, 2026. Based on that evaluation, the

Certifying Officers concluded the Company's disclosure controls

and procedures were effective as of September 30, 2026.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial

reporting during the nine months 2026 that materially affected, or

is reasonably likely to materially affect, our internal control over

financial reporting.

PART II – OTHER INFORMATION

Item 1A. RISK FACTORS

We are not aware of any material changes to the risk factors

included in Item 1A. "Risk Factors" in our Annual Report on Form

10-K for 2025 and Part II, Item 1A. "Risk Factors" in our Quarterly

Report on Form 10-Q for the quarter ended March 31, 2026.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In the three months 2026 we did not issue shares of our common

stock as performance incentive awards to employees. When

issued, these shares are not registered under the Securities Act

of 1933 based on the conclusion that the awards would not be

events of sale within the meaning of Section 2(a)(3) of the Act.

In March 2015 we announced that our Board of Directors had

authorized us to purchase up to $2,000 of our common stock. In

October 2026 our Board of Directors approved an increase of

$3,000 to our existing share repurchase program, bringing the

total share repurchase authorization to $3,033. The manner,

timing and amount of repurchases are determined by

management based on an evaluation of market conditions, stock

price, and other factors and are subject to regulatory

considerations. Purchases may be made from time to time in the

open market, in privately negotiated transactions, accelerated

share repurchase programs or otherwise.

In 2026 we repurchased 3 million shares of our common stock at

a cost of $1,000 under our authorized share repurchase program.

The total dollar value of our shares of common stock that could

be acquired under our authorized repurchase program was $33

as of September 30, 2026.

2026 PeriodTotal Number of Shares Purchased (in millions)Average Price Paid Per SharePurchased as Part of Publicly Announced Plans (in millions)Approximate Dollar Value of Shares that may yet be Purchased Under the Plans
July—$——$1,033
August2.8335.172.883
September0.2321.610.233
Total3$334.463

Item 5. OTHER INFORMATION

Trading Plan Arrangements

Certain of our officers or directors have made elections to

participate in and are participating in, our employee stock

purchase plan and 401(k) plan and have made and may from

time to time make elections to have shares withheld to cover

withholding taxes due or pay the exercise price of stock options,

restricted stock units and performance stock units which may

constitute non-Rule 10b5–1 trading arrangements (as defined in

Item 40. 8(c) of Regulation S-K).

D****isclosure Pursuant to Section 13(r) of the Exchange Act

Section 13(r) of the Exchange Act requires an issuer to disclose

in its annual or quarterly reports whether it or any of its affiliates

knowingly engaged in certain activities, transactions or dealings

relating to parties subject to sanctions administered by the Office

of Foreign Assets Control (OFAC) within the United States

Department of the Treasury, whether or not such activities are

prohibited or sanctionable under United States law. On March 2,

2021 the United States government designated the Russian

Federal Security Service (FSB) under additional sanctions

authorities. On the same day, OFAC issued General License No.

1B (OFAC General License) which generally authorizes certain

licensing, permitting, certification, notification and related

transactions with the FSB as may be required pursuant to

Russian encryption product import controls for the importation,

distribution or use of certain information technology products and

radio frequency technology products in the Russian Federation.

As required under Russian law and as permitted under the OFAC

General License one of our subsidiaries in Russia periodically

files notifications with or applies for import licenses and permits

from the FSB on our behalf in connection with the importation of

our products into Russia. These notification and licensing

activities are free of charge and none of our gross revenue or net

profits are attributable to such activities. We expect to continue to

file notifications with and apply for import licenses and permits

from the FSB to qualify our products for importation and

distribution in the Russian Federation to the extent required

under Russian law but only so long as such notification and

licensing activities are authorized by the OFAC General License,

any successor general license or other authorization issued by

OFAC.

During the three months 2026 we filed three notifications with the

FSB as described above.

21
STRYKER CORPORATION2026 Third Quarter Form 10-Q

Item 6. EXHIBITS

31(i)†Certification of Principal Executive Officer of Stryker Corporation pursuant to Rule 13a-14(a).
31(ii)†Certification of Principal Financial Officer of Stryker Corporation pursuant to Rule 13a-14(a).
32(i)††Certification by Principal Executive Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
32(ii)††Certification by Principal Financial Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
101.INSiXBRL Instance Document
101.SCHiXBRL Schema Document
101.CALiXBRL Calculation Linkbase Document
101.DEFiXBRL Definition Linkbase Document
101.LABiXBRL Label Linkbase Document
101.PREiXBRL Presentation Linkbase Document
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
† Filed with this Form 10-Q
†† Furnished with this Form 10-Q
22
STRYKER CORPORATION2026 Third Quarter Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned thereunto duly authorized.

STRYKER CORPORATION
(Registrant)
Date:October 30, 2026/s/ KEVIN A. LOBO
Kevin A. Lobo
Chair and Chief Executive Officer
Date:October 30, 2026/s/ PRESTON W. WELLS
Preston W. Wells
Vice President, Chief Financial Officer